{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-demonstrates-prolonged-clinical-benefit-as-a-first-line-treatment-for-atypical-egfr-mutated-non-small-cell-lung-cancer-302785924.html", "message": "News view counter 767448 successfully enlarged"}